GlassScriptPhysician profile
John V Dellosso
NPI 1942299920
$23,092.16
in general payments reported to CMS, 2019-2025
57 companies · $3,939 in 2025
The $3,939 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,395 · 2020: $1,949 · 2021: $3,792 · 2022: $3,661 · 2023: $3,851 · 2024: $3,504 · 2025: $3,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,294.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,612.11 | 2019-2025 | Biktarvy, Veklury |
| Viiv Healthcare Company | $3,759.25 | 2019-2025 | Apretude, Dovato, Cabenuva |
| Abbvie INC. | $3,338.26 | 2019-2025 | Vraylar, Mavyret, Synthroid |
| Emd Serono, INC. | $865.40 | 2019-2025 | Serostim |
| Lilly USA, LLC | $750.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $577.34 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $492.06 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Biotech, INC. | $485.67 | 2019-2023 | Symtuza |
| Pfizer INC. | $425.15 | 2019-2025 | |
| Theratechnologies INC. | $420.86 | 2019-2025 | Egrifta, Trogarzo |
| Janssen Pharmaceuticals, INC | $384.41 | 2019-2022 | |
| Almatica Pharma LLC | $372.94 | 2022-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Bausch Health US, LLC | $371.78 | 2019-2023 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $365.12 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $345.43 | 2019-2024 | Trintellix |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dellosso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.